Open AccessEpigenetic Therapy for Epithelioid Sarcoma
Author(s) -
Scott B. Rothbart,
Stephen B. Baylin
Publication year - 2020
Publication title -
cell
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 26.304
H-Index - 776
eISSN - 1097-4172
pISSN - 0092-8674
DOI - 10.1016/j.cell.2020.03.042
Subject(s) - epithelioid sarcoma , biology , ezh2 , prc2 , epigenetics , epigenetic therapy , chromatin , methyltransferase , cancer research , chromatin remodeling , gene silencing , genetics , computational biology , dna methylation , methylation , dna , gene , immunology , gene expression , immunohistochemistry
Tazemetostat is the first epigenetic therapy to gain FDA approval in a solid tumor. This lysine methyltransferase inhibitor targets EZH2, the enzymatic subunit of the PRC2 transcriptional silencing complex. Tumors with mutations in subunits of the SWI/SNF chromatin remodeling complex, inclusive of most epithelioid sarcomas, are sensitive to EZH2 inhibition.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom